

THE LANCET

Infectious Diseases

Supplementary appendix 2

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Doshi RH, Mukadi PK, Casey RM, et al. Immunological response to fractional-dose yellow fever vaccine administered during an outbreak in Kinshasa, Democratic Republic of the Congo: results 5 years after vaccination from a prospective cohort study. *Lancet Infect Dis* 2024; published online Feb 6. [https://doi.org/10.1016/S1473-3099\(23\)00809-5](https://doi.org/10.1016/S1473-3099(23)00809-5).

Supplementary Materials

Table S1. Seropositivity and Geometric Mean Titre at 5 years, by age group and sex (PRNT90) page 2

Table S2: Seropositivity and Geometric Meant Titre at 5 years, by baseline serostatus, age group and sex (PRNT90) page 3

Table S1. Seropositivity and Geometric Mean Titre at 5 years, by age group and sex (PRNT90)

	no./total no.	% (95% CI)	P-value	GMT	P value
All participants	413/566	73.0 (69.2, 76.5)		11.4 (9.9, 13.1)	
Age group, years			0.50		0.66
2-5	83/117	70.9 (62.2, 78.4)		10.4 (7.7, 14.1)	
6-12	110/158	69.6 (62.1, 76.3)		10.6 (8.1, 13.9)	
13-49	124/162	76.5 (69.5, 82.4)		11.8 (9.3, 14.9)	
50+	96/129	74.4 (66.3, 81.2)		13.0 (9.7, 17.5)	
Sex			0.45		0.42
Female	213/286	74.5 (69.1, 79.2)		12.0 (9.9, 14.5)	
Male	200/280	71.4 (65.9, 76.4)		10.8 (8.9, 13.2)	

*Seropositivity was defined as a result on PRNT₉₀ testing of 10 or higher. †Age group represents age at vaccination and not current age. ‡p values for the overall comparisons among the subgroups were calculated with a Fisher's exact test. GMT=Geometric Mean Titre.

Table S2: Seropositivity and Geometric Meant Titre at 5 years, by baseline serostatus, age group and sex (PRNT90)

		Baseline GMT (95% CI)	n/no	Proportion	P value ³	5-year GMT (95% CI)	P value ³
Seronegative at baseline	All participants	NA ⁴	287/429	66.9 (62.3, 71.2)		8.8 (7.5, 10.3)	
	Age group, years				0.0007		0.0004
	2-5	NA	32/63	49.2 (37.3, 61.2)		4.3 (2.9, 6.4)	
	6-12	NA	72/118	61.0 (50.0, 69.3)		7.5 (5.5, 10.2)	
	13-49	NA	110/145	75.9 (68.9, 82.8)		11.4 (8.9, 14.6)	
	≥50	NA	29/74	72.8 (62.5, 79.6)		11.5 (8.2, 16.0)	
	Sex				0.68		0.84
	Female	NA	140/206	68.0 (61.3, 74.0)		8.9 (7.1, 11.2)	
	Male	NA	147/223	65.9 (59.5, 71.8)		8.7 (6.9, 10.9)	
Seropositive at baseline	All participants	50.7 (40.5, 63.5)	126/137	92.0 (86.2, 95.5)		25.6 (20.5, 31.9)	
	Age group, years				0.09		0.62
	2-5	43.2 (32.7, 57.1)	52/54	96.3 (87.5, 99.0)		29.2 (21.8, 39.1)	
	6-12	34.8 (24.9, 48.8)	38/40	95.0 (83.5, 98.6)		29.5 (19.8, 43.8)	
	13-49	115.5 (60.3, 221.3)	14/17	82.4 (59.0, 93.8)		15.7 (7.9, 31.3)	
	≥50	73.8 (36.9, 147.8)	22/26	84.6 (66.5, 93.9)		21.5 (11.7, 39.7)	
	Sex				0.76		0.70
	Female	58.6 (43.3, 79.3)	73/80	91.3 (83.0, 95.7)		25.9 (19.2, 34.9)	
	Male	41.5 (30.0, 57.3)	53/57	93.0 (83.3, 97.2)		25.1 (18.2, 34.8)	

GMT=Geometric Mean Titre. NA=not application. ¹Seropositivity was defined as a result on PRNT₉₀ testing of 10 or higher ²Age group represents age at vaccination and not current age.

³ p values for differences in percent seropositive at 5 years were calculated according to age group and sex using Fisher's exact test; p values for the test of differences in the GMT at 5-year follow-up were calculated using Kruskal-Wallis test (for age group) and Wilcoxon rank-sum test (for sex)